News
Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone payments from Sarepta Therapeutics as ...
There are about $10.5 billion of biotech convertibles outstanding, roughly 3% of the $305 billion market, according to BofA Securities.
Shares of Sarepta Therapeutics fell as much as 8% on Tuesday after the company agreed to comply with the U.S. health regulator's request to pause all shipments of its gene therapy Elevidys in the ...
Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.
George Tidmarsh appointed to lead FDA drug review division amid staffing cuts and scrutiny over accelerated approvals and ...
Shares of drugmaker Sarepta Therapeutics continued to fall Tuesday after the company said it would comply with a Food and Drug Administration request to pause shipments of ...
Sarepta Therapeutics shares were lower in premarket trading on Tuesday, as the drugmaker relented to a Food and Drug Administration request to halt shipments of a gene therapy. Sarepta shares (SRPT) ...
Asian markets are mixed after U.S. stock indexes hit new records on Monday. Oil prices fell and U.S. futures were little ...
The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...
U.S. stock indexes inched to more records to kick off a week full of profit updates from big U.S. companies. The S&P 500 rose 0.1% and squeaked past its prior ...
US stocks advanced midday Monday, with the S&P 500 and Nasdaq Composite notching fresh all-time intraday highs, buoyed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results